Please Wait
Applying Filters...
Menu
Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 5Advate

02 5Kogenate/Kovaltry/ Jivi

03 2Recombinate

04 6Refacto AF/Xyntha

PharmaCompass

01

Brand Name : Refacto AF/Xyntha

Antihemophilic Factor (Recombinant)

arrow
Pharmtech & Ingredients
Not Confirmed

02

Brand Name : Kogenate/Kovaltry/ Jivi

Antihemophilic Factor (Recombinant)

arrow
Pharmtech & Ingredients
Not Confirmed

Brand Name : Kogenate/Kovaltry/ Jivi

arrow
Pharmtech & Ingredients
Not Confirmed

Antihemophilic Factor (Recombinant)

Main Therapeutic Indication : Rare Disorders

Currency : USD

2020 Revenue in Millions : 1,029

2019 Revenue in Millions : 1,067

Growth (%) : -4

blank

03

arrow
Pharmtech & Ingredients
Not Confirmed

04

arrow
Pharmtech & Ingredients
Not Confirmed

05

Brand Name : Refacto AF/Xyntha

Antihemophilic Factor (Recombinant)

arrow
Pharmtech & Ingredients
Not Confirmed

06

Brand Name : Kogenate/Kovaltry/ Jivi

Antihemophilic Factor (Recombinant)

arrow
Pharmtech & Ingredients
Not Confirmed

Brand Name : Kogenate/Kovaltry/ Jivi

arrow
Pharmtech & Ingredients
Not Confirmed

Antihemophilic Factor (Recombinant)

Main Therapeutic Indication : Rare Disorders

Currency : USD

2021 Revenue in Millions : 906

2020 Revenue in Millions : 1,029

Growth (%) : -3

blank

07

arrow
Pharmtech & Ingredients
Not Confirmed

08

Brand Name : Refacto AF/Xyntha

Antihemophilic Factor (Recombinant)

arrow
Pharmtech & Ingredients
Not Confirmed

09

Brand Name : Kogenate/Kovaltry/ Jivi

Antihemophilic Factor (Recombinant)

arrow
Pharmtech & Ingredients
Not Confirmed

Brand Name : Kogenate/Kovaltry/ Jivi

arrow
Pharmtech & Ingredients
Not Confirmed

Antihemophilic Factor (Recombinant)

Main Therapeutic Indication : Hematology

Currency : USD

2022 Revenue in Millions : 889

2021 Revenue in Millions : 906

Growth (%) : -2

blank

10

Brand Name : Kogenate/Kovaltry/ Jivi

Antihemophilic Factor (Recombinant)

arrow
Pharmtech & Ingredients
Not Confirmed

Brand Name : Kogenate/Kovaltry/ Jivi

arrow
Pharmtech & Ingredients
Not Confirmed

Antihemophilic Factor (Recombinant)

Main Therapeutic Indication : Rare Diseases

Currency : USD

2023 Revenue in Millions : 801

2022 Revenue in Millions : 889

Growth (%) : -13

blank